Format

Send to

Choose Destination
Nat Rev Drug Discov. 2011 Jun;10(6):453-71. doi: 10.1038/nrd3403.

Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets.

Author information

1
Vascular Biology & Immunopharmacology Group, Department of Pharmacology, Monash University, Victoria 3800, Australia. grant.drummond@monash.edu

Abstract

NADPH oxidases are a family of enzymes that generate reactive oxygen species (ROS). The NOX1 (NADPH oxidase 1) and NOX2 oxidases are the major sources of ROS in the artery wall in conditions such as hypertension, hypercholesterolaemia, diabetes and ageing, and so they are important contributors to the oxidative stress, endothelial dysfunction and vascular inflammation that underlies arterial remodelling and atherogenesis. In this Review, we advance the concept that compared to the use of conventional antioxidants, inhibiting NOX1 and NOX2 oxidases is a superior approach for combating oxidative stress. We briefly describe some common and emerging putative NADPH oxidase inhibitors. In addition, we highlight the crucial role of the NADPH oxidase regulatory subunit, p47phox, in the activity of vascular NOX1 and NOX2 oxidases, and suggest how a better understanding of its specific molecular interactions may enable the development of novel isoform-selective drugs to prevent or treat cardiovascular diseases.

PMID:
21629295
PMCID:
PMC3361719
DOI:
10.1038/nrd3403
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center